[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

2019 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Ongoing Clinical Trials Study- Companies, Countries, Drugs, Phases, Enrollment, Current Status and Markets

February 2019 | 55 pages | ID: 2E5906D43A0EN
VPAResearch

US$ 2,199.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
The ongoing clinical trial research report- “2019 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Ongoing Clinical Trials Study” analyzes the current scenario of all active Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) trials across the world. The report presents top level analysis of global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) clinical trials across countries, companies and universities. It is designed to provide clear understanding into the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) trials landscape to assist users for effective long term strategy formulation to beat competition.

The report covers a key snapshot of ongoing trial count, average enrollment per trial across countries.

It also segments the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) clinical trials by-
  • Region (Asia Pacific, Europe, Middle East Africa and Americas)
  • Countries
  • Trial Phase
  • Current Trial Status (Recruiting, Active, Planned, Active but Completed Recruiting, Not Yet Recruiting etc)
  • Type of the trial (Interventional, Observational)
  • Sponsor Type (Companies, Universities, Government Bodies etc)
  • Enrollment across types, sponsor types, geographies, current status and phases
The report also identifies the potential drug candidates under development for treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) on the basis of intervention type ongoing Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) trials.

The research work is prepared through extensive and continuous research on Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) trials from over 150 sources including company websites, conferences and presentations, scientific journals, country wise and global clinical trial registries, news, health and science departments among others.

REPORT SCOPE AND COVERAGE:
  • All major ongoing trials from 2010 to 2019 and planned trials are included in the report scope.
  • Drug candidates currently being researched for administering Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) patients are identified
  • The report includes panorama of ongoing Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) clinical trials across the globe
  • Trial Phase, Current Status, Sponsor Type, Location, trial type and Enrollment details are provided
  • Companies and universities focusing on Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) clinical trials are analyzed along with their trial participation (trial title, trial phase and current status)
  • Average Enrollment number, insights into enrollment trends, company wise enrollment are included
  • Both interventional and observational studies are analyzed
  • News and latest developments for the past one year are presented in the report
1. TABLE OF CONTENTS

1.1 List of Figures
1.2 List of Tables

2. EXECUTIVE SUMMARY

2.1 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Ongoing Clinical Trials Overview, 2019
2.2 Premium Insights into Ongoing Clinical Trials
  2.2.1 Ongoing Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Clinical Trials by Region
  2.2.2 Average Enrollment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Clinical Trials
  2.2.3 Companies participating in Ongoing Trials
  2.2.4 Drugs under Study for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Treatment, 2019

3. REGION WISE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP) CLINICAL TRIALS

3.1 Asia Pacific Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Clinical Trials by Country
3.2 Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Clinical Trials by Country
3.3 North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Clinical Trials by Country
3.4 Middle East and Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Clinical Trials by Country
3.5 South and Central America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Clinical Trials by Country

4. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP) CLINICAL TRIAL TRENDS

4.1 Start Year wise Ongoing Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Clinical Trials
4.2 Phase wise Ongoing Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Clinical Trials
4.3 Trial Status wise Ongoing Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Clinical Trials
4.4 Trial Type wise Ongoing Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Clinical Trials

5. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP) AVERAGE ENROLLMENT TRENDS

5.1 Average Enrollment in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Trials by Year
5.2 Average Enrollment in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Trials by Phase
5.3 Average Enrollment in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Trials by Status
5.4 Average Enrollment in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Trials by Type of Trial

6. COMPANIES PARTICIPATING IN ONGOING CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP) CLINICAL TRIALS

6.1 Ongoing Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Trials by Sponsor Type
6.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Average Enrollment by Sponsor Type
6.3 Subjects Recruited by Leading Sponsors

7 TRIAL SNAPSHOTS- PHASE, TYPE, TITLE, LOCATION, START YEAR, COMPLETION YEAR, RECRUITMENT STATUS, ENROLLMENT, PARTICIPATING COUNTRIES, TRIAL LOCATIONS, COMPANY, DRUGS AND OTHER DETAILS

7.1 Ongoing Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Trials- Phase
7.2 Ongoing Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Trials- Phase
7.3 Ongoing Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Trials- Phase
7.4 Ongoing Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Trials- Phase

8. APPENDIX

8.1 Report Guidance
8.2 Research Methodology
8.3 Abbreviations
8.4 Definitions
8.5 Sources
8.6 Publisher Expertise

LIST OF FIGURES

Figure 1: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Ongoing Clinical Trials by Region, 2019
Figure 2: Country wise Clinical Trials, 2019
Figure 3: Country wise Average Enrolment, 2019
Figure 4: Asia Pacific – Country wise Ongoing Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Clinical Trials and Enrolment
Figure 5: Europe – Country wise Ongoing Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Clinical Trials and Enrolment
Figure 6: Middle East Africa – Country wise Ongoing Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Clinical Trials and Enrolment
Figure 7: North America – Country wise Ongoing Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Clinical Trials and Enrolment
Figure 8: South and Central America – Country wise Ongoing Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Clinical Trials and Enrolment
Figure 9: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Ongoing Clinical Trials by Phase
Figure 10: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Ongoing Clinical Trials by Trial Status
Figure 11: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Ongoing Clinical Trials by Type
Figure 12: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Ongoing Clinical Trials by Sponsor Type
Figure 13: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Ongoing Clinical Trials by Leading Sponsors
Figure 14: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Average Enrollment by Phase
Figure 15: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Average Enrollment by Trial Status
Figure 16: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Average Enrollment by Type
Figure 17: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)- Average Enrolment by Type of Sponsors
Figure 18: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)- Enrolment by Leading Sponsors
Figure 19: VPAResearch- Research Methodology

LIST OF TABLES

Table 1: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Ongoing Clinical Trials Snapshot- 2019
Table 2: Ongoing Trials by Region, 2019
Table 3: Country wise Clinical Trials and Average Enrolment by Country, 2019
Table 4: Asia Pacific – Country wise Ongoing Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Clinical Trials and Enrolment
Table 5: Europe – Country wise Ongoing Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Clinical Trials and Enrolment
Table 6: Middle East Africa – Country wise Ongoing Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Clinical Trials and Enrolment
Table 7: North America – Country wise Ongoing Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Clinical Trials and Enrolment
Table 8: South and Central America – Country wise Ongoing Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Clinical Trials and Enrolment
Table 9: Clinical Trials by Phase
Table 10: Clinical Trials by Trial Status
Table 11: Clinical Trials by Type
Table 12: Clinical Trials by Sponsor Type
Table 13: Clinical Trials by Leading Sponsors
Table 14: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Average Enrollment by Phase
Table 15: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Average Enrollment by Trial Status
Table 16: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Average Enrollment by Type
Table 17: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)- Average Enrolment by Type of Sponsors
Table 18: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)- Enrolment by Leading Sponsors


More Publications